[Febrile neutropenia in children who have leukemia]

Meliha Sakić1

  • 1Pedijatrijska Klinika, Klinicki Centar Univerziteta u Sarajevu.

Medicinski Arhiv
|January 5, 2005
PubMed

Insights

Febrile neutropenia is a frequent complication in children with malignant diseases. Prompt antibiotic therapy is crucial, as infections, including sepsis, are common causes.

Area of Science:

  • Pediatric Hematology-Oncology
  • Infectious Diseases in Immunocompromised Patients

Context:

  • Febrile neutropenia is a significant complication in children undergoing treatment for malignant conditions.
  • Prompt recognition and management of fever are critical, as it is often indicative of infection.
  • Established protocols for managing febrile neutropenia are essential for timely intervention.

Purpose:

  • To analyze the incidence and causes of febrile neutropenia in pediatric leukemia patients.
  • To identify common pathogens responsible for infections in this vulnerable population.
  • To evaluate the microbiological findings in children with febrile neutropenia.

Summary:

  • A study of 83 children with leukemia found that 49.4% experienced febrile neutropenia.
  • Infections were identified in 65% of these cases, with sepsis being the most common.
  • Commonly isolated pathogens included Gram-positive bacteria (55%), Gram-negative bacteria (25%), and fungi (20%).

Impact:

  • Highlights the high prevalence of infections, including sepsis, in pediatric febrile neutropenia.
  • Emphasizes the importance of microbiological investigations for targeted antimicrobial therapy.
  • Underscores the need for strict isolation and aseptic techniques to prevent superinfections.
Abstract

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...